LUNAR Trial Update: ¹⁷⁷Lu-PNT2002 Before SBRT in Oligorecurrent Prostate Cancer

Coverage, in order

1. 1h ago
   
   OncoDaily obscure study

   LUNAR Trial Update: ¹⁷⁷Lu-PNT2002 Before SBRT in Oligorecurrent Prostate Cancer

   Metastasis-directed therapy with stereotactic body radiotherapy (SBRT) has been shown to improve progression-free survival in patients with oligorecurrent hormone-sensitive prostate cancer (orHSPC). Although SBRT can provide effective local control of

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.